WOBURN, Mass., Jan. 2 /PRNewswire/ -- BioVex Inc today announced that it will present at the JPMorgan 26th Annual Healthcare Conference at 2:30 p.m. PT on Wednesday, January 9, 2008. The conference is being held at Westin St. Francis in San Francisco, California.
About BioVex
BioVex is an end-of-Phase II clinical-stage biotechnology company based in Woburn, MA, focused on the development and commercialization of biological treatments for cancer and the prevention of infectious disease. The company has two proprietary technology platforms: OncoVEX and ImmunoVEX.
BioVex’s lead cancer program, OncoVEX GM-CSF, is an oncolytic vaccine that selectively destroys tumor cells accompanied by the induction of a systemic immune response. OncoVEX GM-CSF is currently completing a Phase II clinical trial for melanoma and Phase I/II clinical trials for head & neck cancer and pancreatic cancer. Data from these studies has been very encouraging demonstrating OncoVEX GM-CSF has the potential to treat both local and metastatic disease. The Company is currently preparing for an initial registration study in melanoma where multiple overall durable complete and partial responses have been demonstrated in an ongoing Phase II trial testing OncoVEX GM-CSF as stand alone therapy in patients with un-resectable stage IIIc and stage IV metastatic disease. The Company plans to make an SPA submission to the FDA early in the first quarter of 2008.
The Company’s second program is a rationally designed live attenuated vaccine for genital herpes, ImmunoVEX HSV2, based on the novel concept of removing key genes responsible for immune evasion. The vaccine provides complete protection in animal models of the disease. A Phase I study with ImmunoVEX HSV2 is scheduled to commence in the first quarter of 2008.
CONTACT: Philip Astley-Sparke President & CEO of BioVex Inc, +1-781-376-
4913, pastleysparke@biovex.com; or John Capodanno of FD Life Sciences,
+1-212- 850-5705, john.capodanno@fd.com
